Purpose: To compare outcomes of bone marrow transplants for leukemia from HLA-identical siblings, haploidentical HLA-mismatched relatives, and HLAmatched and mismatched unrelated donors.
METHODS

Population
The study included recipients of allogeneic bone marrow transplants reported to the IBMTR with the following: (1) chronic myelogenous leukemia (CML), acute myelogenous leukemia (AML), or acute lymphoblastic leukemia (ALL); (2) transplantation performed between 1985 and 1991; (3) serologic typing for HLA-A, -B, and -DR of donor and recipient; and (4) donors who were either HLA-identical siblings, haploidentical relatives serologically mismatched for one or two HLA-A, -B, or -DR antigens, or unrelated persons serologically mismatched for no or one HLA-A, -B, or -DR antigen. The HLA-identical sibling cohort was restricted to persons receiving non-T-cell-depleted transplants with posttransplant methotrexate and cyclosporine at centers where alternative donor transplants were also performed. This was the most common approach used for HLA-identical sibling transplants during the study period, accounting for approximately two thirds of such transplants, and the approach associated with the highest leukemiafree survival in a previous IBMTR study. 3 7 A total of 2,055 transplants at 87 institutions fulfilled these criteria.
Histocompatibility
Donor-recipient histocompatibility was determined by results of serologic typing for HLA-A, -B, and -DR antigens as reported by institutions performing the transplants. All HLA data were reviewed by two of the authors (M.M.H., J.Jv.R.). Additional family typings were available for 584 patients. Definitions of HLA-matching were considered with respect to reagents available when typing was performed. Transplants were classified as HLA-mismatched if detectable donor-recipient disparity was reported, whether or not this disparity was within an HLA cross-reactive group. The degree of certainty of serologic matching was further evaluated in light of reagents currently available for use. For 67% of alternative donorrecipient pairs, further splitting of HLA antigens is now possible with currently available antisera. Most (58%) of the uncertain typing was caused by failure to split DR antigens 2, 3, 5, and 6 into narrower specificities. Adjustment for the degree of certainty of serologic match was made in all multivariate analyses by entering a covariate designating the number of loci for which further splitting could be performed. Donor-recipient relationship and histocompatibility are listed in Table 1 .
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mia-free survival. Graft failure was analyzed in patients who survived 21 days posttransplant using published criteria 3 8 ; those who never engrafted, as well as those with transient engraftment, were considered to have graft failure. Acute GVHD was defined as moderate to severe (grade II to IV) disease using published criteria 39 ; patients who survived more than 21 days with engraftment were considered at risk. Chronic GVHD was determined by clinical criteria in patients who survived more than 90 days with engraftment. 40 Relapse was defined as hematologic or clinical recurrence in any site; patients in continuous complete remission were censored at death or, for survivors, at last contact. Transplant-related mortality was defined as death in continuous complete remission; patients were censored at time of relapse or at last follow-up evaluation. Leukemia-free survival was defined as survival in continuous complete remission; relapse and death from causes other than leukemia were considered treatment failures, whereas patients who were alive and in remission were censored at last follow-up evaluation.
Statistical Methods
Patient, disease, and transplant characteristics of groups were compared using the X 2 statistic for categorical variables and the Mann-Whitney for continuous variables. Univariate probabilities of transplant outcomes were calculated using the Kaplan-Meier method. Associations between donor type and relapse, transplant-related mortality, and leukemia-free survival were evaluated using Cox proportional hazards regression models.4 Potential confounding factors considered in the analysis were donor and recipient age; donorrecipient sex match; donor and recipient cytomegalovirus (CMV) status; pretransplant Karnofsky performance score; disease; remission status; WBC count at diagnosis; conditioning regimen; GVHD prophylaxis; time from diagnosis to transplant; certainty of HLA serologic match (see above); and year of transplant, using a forward stepwise variable selection approach. Interactions between donor type and leukemia type, remission status, and waiting time to transplant were also considered. For each set of factors, a test of the appropriateness of the proportional hazards model was made using a time-dependent covariate model. Based on results of these tests, subsequent analyses were stratified on covariates with nonproportional hazards: acute versus chronic leukemia and conditioning regimen for transplant-related mortality; performance score (< and 90) and remission status for relapse; and performance score for leukemia-free survival. Using the appropriate stratified Cox model, a stepwise variable selection procedure was used to determine which of the remaining covariates were associated with outcome, using a .1 significance level. In each step, covariates for donor type were included in the model. Interactions between donor type and covariates found to be significant in the stepwise procedure were tested in multivariate analysis. This analysis also tested which categories could be collapsed for factors with more than two levels. Pairwise comparisons between donor types were made from a final multivariate Cox model, adjusting for relevant risk factors.
The IBMTR
The IBMTR is a voluntary working group of more than 300 transplant teams worldwide that contributes detailed data on their allogeneic and identical twin bone marrow transplants to a Statistical Center at the Health Policy Institute of the Medical Coliege of Wisconsin. 4 2 Participants must report all consecutive transplants. Approximately 60% of active allogeneic transplant cer:ers worldwide report their data to the IBMTR. The IBMTR data base includes 40% to 45% of all allogeneic transplants performed since 1970. Patients are followed-up longitudinally. Computerized error checks, physician review of submitted data, and on-site audits of participating centers ensure data quality.
RESULTS
Patients
Donor-recipient relationship and histocompatibility are listed in Table 1 . There were 1,224 transplants from HLAidentical siblings, 340 from HLA-mismatched relatives, and 491 from unrelated donors.
Patient and disease characteristics are listed in Table   2 . There were several differences among recipients of HLA-identical sibling, HLA-mismatched related, and unrelated donor transplants. Recipients of alternative donor transplants tended to have lower pretransplant performance scores, more advanced disease, and higher WBC at diagnosis than recipients of HLA-identical sibling transplants. Recipients of HLA-mismatched related donor transplants tended to be younger than recipients of unrelated donor or HLA-identical sibling transplants.
The proportion of unrelated-donor transplants for CML was significantly higher than for related-donor trans-
plants. Fewer recipients of unrelated-donor transplants
were CMV-seropositive pretransplant. The interval between diagnosis and transplant was shortest for HLAidentical sibling transplants, longer for alternative related-donor transplants, and longest for unrelated-donor transplants.
Transplant Regimens
Transplant characteristics are listed in Table 3 . Alternative donors tended to be older than HLA-identical sibling donors. The intensity of pretransplant conditioning tended to be higher for alternative-donor transplants, with more patients receiving greater than 12 Gy total-body irradiation (TBI) and drugs in addition to cyclophosphamide. Regimens without TBI were less frequently used in alternative-donor transplants. By study design, there were no T-cell-depleted HLA-identical sibling transplants, and all recipients of HLA-identical sibling transplants received methotrexate and cyclosporine posttransplant for GVHD prophylaxis. Forty-nine percent of HLA-mismatched related-donor transplants and 39% of unrelateddonor transplants were T-cell-depleted. Table 4 lists probabilities of graft failure, acute GVHD, and chronic GVHD by donor type unadjusted for differences in prognostic variables. Alternative donor transplants were associated with higher probabilities of each outcome than HLA-identical sibling trans- plants. The increase in acute GVHD was primarily in grades III to IV. Table 5 lists unadjusted 2-year probabilities of transplant-related mortality, relapse, and leukemia-free survival (Fig 1) after transplants for early (first chronic phase or first remission), intermediate (accelerated or second chronic phase or -second remission), and advanced (blast phase or relapse) leukemia by donor type. In general, transplant-related mortality was higher, relapse similar, and leukemia-free survival lower after alternative-donor transplants than after HLA-identical sibling transplants.
Univariate Analyses
Multivariate Analyses
Relative risks of transplant-related mortality, compared with HLA-identical sibling transplants (relative risk 1.00) and adjusted for relevant prognostic variables, are shown in Fig 2. Transplant-related mortality was higher after all types of alternative donor transplants. Figure 2 also gives P values for comparisons of transplant-related mortality between transplants from different types of alternative donors. Risks were higher after 2-HLA-antigen-mismatched related versus 1-HLA-antigen-mismatched related-donor transplants and after 1-HLA-antigen-mismatched unrelated versus HLA-matched unrelated-donor transplants. Transplant-related mortality rates after l-HLA-antigen-mismatched related-donor and HLA-matched unrelated-donor transplants were similar, as were transplant-related mortality rates after 2-HLA-antigen mismatched related-donor and 1-HLA-antigen-mismatched unrelated-donor transplants. Other variables associated Abbreviations: TRM, transplant-related mortality; LFS, leukemia-free survival. 'P value for comparison with HLA-identical sibling transplants. tEarly leukemia = first remission or chronic phase; intermediate leukemia = second remission or accelerated phase; advanced leukemia = not in remission or in blast phase.
with higher transplant-related mortality were older recipient age (P < .001), pretransplant performance score less than 90% (P < .001), intermediate or advanced versus early leukemia (P < .0001), interval from diagnosis to transplant greater than 2 years (P < .04 for acute leukemia; P < .0001 for CML), female to male transplant (P < .03), use of less intense conditioning regimens (P < .002), and use of GVHD prophylaxis regimens other than cyclosporine and methotrexate for alternative-donor transplants (P < .0001).
Associations between donor type and relapse differed for acute leukemia and CML (Fig 3) . In acute leukemia, relapse risk was lower after alternative-donor compared with HLA-identical sibling transplants. This difference was statistically significant (P < .05) only for 2-HLA-antigen-mismatched related and -HLAantigen-mismatched unrelated donors. In CML, recipients of HLA-mismatched related-donor transplants had a higher risk of relapse than recipients of HLA-identical sibling or unrelated-donor transplants. This persisted after stratification by disease state and after excluding T-cell-depleted transplants. Relapse risk was similar after unrelated and HLAidentical sibling transplants for CML. P values for comparisons of relapse risk between various types of alternative donor transplants are also given in Fig 3. Other variables associated with increased relapse risk were young recipient age (P < .02), advanced disease (P < .0001), high WBC count at diagnosis (P < .006), interval between diagnosis and transplant greater than 2 years in CML (P < .05), less intense conditioning regimens (P < .0001), and T-cell depletion of alternative-donor bone marrow (P < .0003).
Associations between donor type and treatment failure depended on leukemia state pretransplant (Fig 4) . In patients with early leukemia, treatment failure was significantly higher with all types of alternative donors than with HLA-identical sibling donors. Among alternative donors, recipients of transplants from HLA-matched unrelated donors had a lower risk of treatment failure than those who received transplants from 1-HLA-antigenmismatched unrelated donors (relative risk for matched v mismatched unrelated donors 0.61; P = .0028) or from 2-HLA-antigen-mismatched related donors (relative risk for matched unrelated v 2-HLA-antigen-mismatched related donors 0.55; P = .024). Risk of treatment failure after HLA-matched unrelated-donor transplants was similar to risk after 1-HLA-antigen-mismatched related-donor transplants (relative risk for matched unrelated v 1-HLA-antigen-mismatched related donors 1.20; P = NS).
For patients with more advanced leukemia, risks of treatment failure after transplants from HLA-identical siblings and 1-HLA-antigen-mismatched related donors were similar. Treatment failure with other types of alter- failure (lower leukemia-free survival) were older recipient age (P < .003), high WBC count at diagnosis (P < .02), interval between diagnosis and transplant greater than 2 years (P < .003), and less intense conditioning regimens (P < .004). 1'
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DISCUSSION
From 1990 to 1991, approximately 30% of patients younger than 55 years of age with CML, 25% of those with AML, and 10% of those with ALL received an allogeneic transplant according to a survey of 10 countries in Europe and North America. 43 Approximately 85% of these transplants were from HLA-identical sibling donors. Most patients considered for bone marrow transplant do not have an HLA-identical sibling. ' This study analyzed outcome of transplants from four types of alternative donors: transplants from haploidentical relatives serologically mismatched for one HLA-A, -B, or -DR antigen, from haploidentical relatives mismatched for two HLA antigens, from unrelated donors serologically matched for all HLA-A, -B, and -DR antigens, and from unrelated donors serologically mismatched for one HLA antigen. We compared results with HLA-identical sibling transplants. In general, transplantrelated mortality was higher and leukemia-free survival lower with alternative donors than with HLA-identical siblings, despite adjustments for differences in prognostic factors and time to transplant. Transplant-related mortality was greater than 50% in all alternative-donor transplant groups and resulted from increased graft failure and increased acute and chronic GVHD. Contrary to expectations, increased GVHD did not significantly decrease re-
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Matched Unrelated lapse. Alternative-related donor transplants were actually associated with increased relapse risk in CML. This finding was not explained by differences in disease state, time to transplant, or use of T-cell depletion. We lacked sufficient data to determine whether diverse T-cell depletion techniques had different risks of relapse; this is the subject of an on-going IBMTR study.44 In acute leukemia, relapse risk was reduced by 1.5-to threefold, but this was insufficient to offset increased transplant-related mortality.
Results of alternative-donor transplants correlated with leukemia state, donor-recipient relationship, and degree of HLA matching. Transplant-related mortality rates with l-HLA-antigen-mismatched related and HLA-matched unrelated donors were similar, with risks 1.5 to two times higher than HLA-identical sibling transplants. Transplantrelated mortality rates with 2-HLA-antigen-mismatched related-donor and 1-HLA-antigen unrelated-donor transplants were similar but approximately three times higher than HLA-identical sibling transplants. For patients with early leukemia, this resulted in adjusted risks of treatment failure approximately 2.0 (with l-HLA-antigen-mismatched related and HLA-matched unrelated donors) to 3.5 (with other alternative donors) times higher than in comparable patients who received HLA-identical sibling transplants. For patients with more advanced leukemia, differences in outcome were less striking. Treatment failure after 1-HLA-antigen-mismatched related-donor transplants was similar to HLA-identical sibling transplants, and risk with other alternative donors was increased by only approximately 50%. This is primarily 
